Incidence Rates of Bleeding and Emergency Surgery Due to Trauma or Fracture Among Japanese Patients with Non-valvular Atrial Fibrillation Receiving Oral Anticoagulation Therapy
Tóm tắt
Từ khóa
Tài liệu tham khảo
Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146:857–67.
Inoue H, Nozawa T, Hirai T, et al. Accumulation of risk factors increases risk of thromboembolic events in patients with nonvalvular atrial fibrillation. Circ J. 2006;70:651–6.
Fuster V, Ryden LE, Cannom DS, et al. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2011;123:e269–367.
De Caterina R, Husted S, Wallentin L, et al. Vitamin K antagonists in heart disease: current status and perspectives (section III). Position paper of the ESC working group on thrombosis—task force on anticoagulants in heart disease. Thromb Haemost. 2013;110:1087–107.
Ageno W, Gallus AS, Wittkowsky A, et al. Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141:e44S–e88S.
Hirsh J, Dalen JE, Anderson DR, et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest. 1998;114:445S–S46969.
Heidbuchel H, Verhamme P, Alings M, et al. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace. 2015;17:1467–507.
Yorkgitis BK, Zhang J, Rappold JF. Non-vitamin K antagonist oral anticoagulants: the clinician's new challenge. J Am Osteopath Assoc. 2015;115:612–21.
Kaatz S, Kouides PA, Garcia DA, et al. Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. Am J Hematol. 2012;87(Suppl 1):S141–S145145.
Omae T, Koh K, Kumemura M, Sakuraba S, Katsuda Y. Perioperative management of patients with atrial fibrillation receiving anticoagulant therapy. J Anesth. 2019;33:551–61.
Thomas S, Makris M. The reversal of anticoagulation in clinical practice. Clin Med (Lond). 2018;18:314–9.
Ministry of Internal Affairs and Communication. Elderly people in Japan—a view from the statistics. 2019. https://www.stat.go.jp/data/topics/pdf/topics97.pdf. Accessed Sep 2019
Kojima M, Endo A, Shiraishi A, Otomo Y. Age-related characteristics and outcomes for patients with severe trauma: analysis of Japan's nationwide trauma registry. Ann Emerg Med. 2019;73:281–90.
Nishimura T, Naito H, Matsuyama S, et al. Geriatric trauma in patients ≥ 85 years old in an urban district of Japan. Acta Med Okayama. 2019;73:197–203.
Kubota K, Ooba N, Kamijima Y, Sato K, Koide D. The use of anticoagulants in patients with non-valvular atrial fibrillation between 2005 and 2014: a drug utilization study using claims data in Japan. PLoS ONE. 2018;13:e0203380.
Ohshima A, Koyama T, Ogawa A, et al. Oral anticoagulants usage in Japanese patients aged 18–74 years with non-valvular atrial fibrillation: a retrospective analysis based on insurance claims data. Fam Pract. 2019;36:685–92.
Tanaka S, Seto K, Kawakami K. Pharmacoepidemiology in Japan: medical databases and research achievements. J Pharm Health Care Sci. 2015;1:16.
Urushihara H, Taketsuna M, Liu Y, et al. Increased risk of acute pancreatitis in patients with type 2 diabetes: an observational study using a Japanese hospital database. PLoS ONE. 2012;7:e53224.
Amin A, Keshishian A, Trocio J, et al. Risk of stroke/systemic embolism, major bleeding and associated costs in non-valvular atrial fibrillation patients who initiated apixaban, dabigatran or rivaroxaban compared with warfarin in the United States Medicare population. Curr Med Res Opin. 2017;33:1595–604.
Li XS, Deitelzweig S, Keshishian A, et al. Effectiveness and safety of apixaban versus warfarin in non-valvular atrial fibrillation patients in "real-world" clinical practice. A propensity-matched analysis of 76,940 patients. Thromb Haemost. 2017;117:1072–82.
Lip GY, Keshishian A, Kamble S, et al. Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin. A propensity score matched analysis. Thromb Haemost. 2016;116:975–86.
Lee KT, Chang SH, Yeh YH, et al. The CHA(2)DS(2)-VASc score predicts major bleeding in non-valvular atrial fibrillation patients who take oral anticoagulants. J Clin Med. 2018;7:338.
Nielsen PB, Skjoth F, Sogaard M, et al. Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. BMJ. 2017;356:j510.
Koretsune Y, Etoh T, Katsuda Y, et al. Risk profile and 1-year outcome of newly diagnosed atrial fibrillation in Japan—insights from GARFIELD-AF. Circ J. 2018;83:67–74.
Kitazono T, Ikeda T, Ogawa S, et al. Real-world outcomes of rivaroxaban treatment in elderly Japanese patients with nonvalvular atrial fibrillation. Heart Vessels. 2020;35:399–408.
Nishida T, Okumura Y, Yokoyama K, et al. Oral anticoagulant use and clinical outcomes in elderly Japanese patients: findings from the SAKURA AF Registry. Heart Vessels. 2019;34:2021–30.
Okumura Y, Yokoyama K, Matsumoto N, et al. Three-year clinical outcomes associated with warfarin vs. direct oral anticoagulant use among Japanese patients with atrial fibrillation—findings from the SAKURA AF registry. Circ J. 2018;82:2500–9.
Koretsune Y, Yamashita T, Yasaka M, et al. Comparative effectiveness and safety of warfarin and dabigatran in patients with non-valvular atrial fibrillation in Japan: a claims database analysis. J Cardiol. 2019;73:204–9.
Wong H, Lovett N, Curry N, Shah K, Stanworth SJ. Antithrombotics in trauma: management strategies in the older patients. J Blood Med. 2017;8:165–74.
Kudo D, Miyakoshi N, Hongo M, et al. An epidemiological study of traumatic spinal cord injuries in the fastest aging area in Japan. Spinal Cord. 2019;57:509–15.
Orimo H, Yaegashi Y, Hosoi T, et al. Hip fracture incidence in Japan: estimates of new patients in 2012 and 25-year trends. Osteoporos Int. 2016;27:1777–844.
Okuno K. Current status and future of traumatic brain injury treatment in Japan [in Japanese]. Jpn J Neurosurgery (Tokyo). 2018;27:17–24.